Key result
Elevated choline is linked to ~33% higher risk of incident heart failure.
Why the study?
Do elevated circulating levels of choline pathway metabolites predict the development of new-onset heart failure and adverse outcomes in patients with established heart failure?
Meta-Analysis (n=267,569)
Do elevated circulating levels of choline pathway metabolites predict the development of new-onset heart failure and adverse outcomes in patients with established heart failure?
Answers are grounded in this paper and cite their sources.
Elevated circulating levels of choline pathway metabolites, particularly choline and phosphatidylcholine, are significantly associated with an increased risk of developing new-onset heart failure and adverse outcomes in established heart failure.
Background Metabolomics has emerged as a powerful tool to elucidate novel biomarkers and mechanisms in heart failure (HF) pathophysiology. Choline and its metabolites—phosphatidylcholine (PC), trimethylamine N-oxide (TMAO), betaine, and dimethylglycine (DMG)—play crucial roles in metabolism, inflammation, and cardiovascular function, yet their associations with HF risk and progression remain incompletely understood. Purpose This systematic review and meta-analysis aimed to evaluate the relationship between circulating levels of choline, PC, TMAO, betaine, and DMG with the development of new-onset HF and adverse clinical outcomes in patients with established HF. Methods A comprehensive search of MEDLINE, EMBASE, and PubMed was conducted from inception to February 2025. Prospective cohort studies examining plasma choline, PC, TMAO, betaine, and DMG in relation to HF incidence or adverse clinical outcomes were included. Pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated using random-effects meta-analyses. Results Nine prospective cohort studies comprising ten populations (n=267,569) were analysed. Elevated choline levels were significantly associated with increased HF incidence (HR 1.33, 95% CI 1.07–1.66, p=0.0107). In patients with HF, choline showed a positive but non-significant association with a composite of adverse HF outcomes (HR 1.13, 95% CI 0.91–1.40, p=0.2737). Higher PC levels were significantly associated with an increased HF incidence (HR 1.25, 95% CI 1.16–1.34, p<0.0001). Among patients with established HF, elevated betaine levels were significantly associated with a composite of adverse clinical outcomes, including cardiovascular death, all-cause mortality, and HF hospitalisation (HR 1.15, 95% CI 1.02–1.30, p=0.0206). TMAO, DMG, and betaine showed a trend towards increased HF incidence. Conclusions This meta-analysis provides evidence that metabolites in the choline pathway predict the development of HF. These findings highlight the potential of choline-related metabolites as biomarkers for HF risk stratification and prognosis. Understanding the mechanism whereby the choline pathway leads to HF and its adverse outcomes may lead to novel therapeutic targets for HF prevention and management.
No takes yet. Share an insight, caveat, or question.
Shokravi et al. (2025) conducted a meta-analysis in Heart failure (n=267,569). Elevated choline levels was evaluated on Heart failure incidence (HR 1.33, 95% CI 1.07-1.66, p=0.0107). Elevated choline levels were associated with an increased incidence of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: